<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02804815</url>
  </required_header>
  <id_info>
    <org_study_id>14/0814</org_study_id>
    <secondary_id>2013-004398-28</secondary_id>
    <secondary_id>120104</secondary_id>
    <nct_id>NCT02804815</nct_id>
  </id_info>
  <brief_title>Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours</brief_title>
  <official_title>A Phase III, Double-blind, Placebo-controlled, Randomised Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Add-Aspirin aims to assess whether regular aspirin use after standard curative therapy can&#xD;
      prevent recurrence and improve survival in individuals with non-metastatic common tumours.&#xD;
      The question will be assessed in four different tumour types (breast, colorectal,&#xD;
      gastro-oesophageal and prostate) by means of parallel cohorts within an overarching trial&#xD;
      protocol.&#xD;
&#xD;
      Eligible participants will be randomly assigned (double-blind) to either aspirin 100mg,&#xD;
      aspirin 300mg or a matched placebo, to be taken daily for at least 5 years. Disease&#xD;
      recurrence and survival will be assessed, along with adherence, toxicity, and other potential&#xD;
      effects of aspirin (eg. cardiovascular).&#xD;
&#xD;
      There is a large body of evidence indicating that aspirin has anti-cancer effects.&#xD;
      Meta-analyses of cardiovascular trials of aspirin have shown short-term effects on cancer&#xD;
      mortality and a decrease in risk of metastases, suggesting a role for aspirin in the&#xD;
      treatment as well as prevention of cancer. Additionally, large observational studies of&#xD;
      individuals taking aspirin after cancer treatment have shown improved disease-specific and&#xD;
      overall mortality for specific tumour types.&#xD;
&#xD;
      In the treatment setting, the risks of side effects associated with aspirin are expected to&#xD;
      be outweighed by potential benefits. However, this has not yet been assessed in a randomised&#xD;
      trial.&#xD;
&#xD;
      As a low cost, generic and widely available drug, which is generally safe, if aspirin is&#xD;
      shown to be effective, it could have a huge impact on cancer outcomes globally.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase III, multi-centre, double-blind, placebo-controlled randomised trial which aims to&#xD;
      assess whether regular aspirin use after standard therapy prevents recurrence and prolongs&#xD;
      survival in participants with non-metastatic common solid tumours.&#xD;
&#xD;
      The trial has four parallel tumour site-specific cohorts (breast, colorectal,&#xD;
      gastro-oesophageal and prostate cancer). An overarching protocol ensures each cohort is as&#xD;
      comparable as possible to allow a combined analysis of overall survival as a co-primary&#xD;
      outcome measure in addition to individual tumour site-specific analyses of disease recurrence&#xD;
      and survival.&#xD;
&#xD;
      Participants who have undergone potentially curative treatment (surgery or other radical&#xD;
      treatment), including any standard neo-adjuvant or adjuvant therapy for breast, colorectal,&#xD;
      gastro-oesophageal or prostate cancer or have participated in any pre-approved trials and&#xD;
      satisfy the eligibility criteria.&#xD;
&#xD;
      Participants will be randomly assigned to 100mg aspirin, 300mg aspirin or matched placebo.&#xD;
      All tablets will be enteric-coated to be taken daily for at least five years. Prior to&#xD;
      randomisation, all potential participants will take open-label 100mg aspirin daily for a&#xD;
      run-in period of approximately 8 weeks to assess tolerability and adherence.&#xD;
&#xD;
      The trial incorporates a feasibility phase during which recruitment feasibility, treatment&#xD;
      adherence, safety and use of the run-in period will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2026</completion_date>
  <primary_completion_date type="Anticipated">October 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>10 years follow up</time_frame>
    <description>Overall survival of all cohorts combined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Invasive disease-free survival (IDFS)</measure>
    <time_frame>6 years follow up</time_frame>
    <description>IDFS in the breast cancer cohort</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>6 years follow up</time_frame>
    <description>DFS in the colorectal cancer cohort</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years follow up</time_frame>
    <description>Overall survival in the gastro-oesophageal cancer cohort</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemical recurrence-free survival (bRFS)</measure>
    <time_frame>5 years follow up</time_frame>
    <description>bRFS in the prostate cancer cohort</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>5 years follow up</time_frame>
    <description>Patient-reported compliance (via diary card) will be assessed during the run-in period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with serious haemorrhage (grade 3 or above) as measured by CTCAE V4.0. Data will be collected on case report forms.</measure>
    <time_frame>5 years follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related (active drug and placebo) cardiovascular events as assessed by CTCAE v4.0</measure>
    <time_frame>5 years follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with second malignancies as assessed by case report form</measure>
    <time_frame>5 years follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that show a decline in cognition and extent of decline as assessed by the Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>5 years follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">11000</enrollment>
  <condition>Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Gastro-oesophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Aspirin 100mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 100mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100mg Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin 300mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 300mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 300mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>300mg Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 100mg</intervention_name>
    <description>Aspirin 100mg</description>
    <arm_group_label>Aspirin 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 300mg</intervention_name>
    <description>Aspirin 300mg</description>
    <arm_group_label>Aspirin 300mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 100mg</intervention_name>
    <description>Placebo 100mg</description>
    <arm_group_label>Placebo 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 300mg</intervention_name>
    <description>Placebo 300mg</description>
    <arm_group_label>Placebo 300mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        COMMON INCLUSION CRITERIA&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  WHO performance status 0, 1 or 2&#xD;
&#xD;
          -  Participants should not be and have no intention of pregnancy or breast feeding during&#xD;
             trial treatment&#xD;
&#xD;
          -  Previous or current participants of other primary treatment trials if agreed in&#xD;
             advance between trials&#xD;
&#xD;
          -  No clinical or radiological evidence of residual or distant disease&#xD;
&#xD;
        BREAST COHORT INCLUSION CRITERIA&#xD;
&#xD;
          -  Men or women with histologically confirmed invasive breast cancer&#xD;
&#xD;
          -  Undergone complete primary invasive tumour excision with clear margins&#xD;
&#xD;
          -  Surgical staging of the axilla must have been undertaken by sentinel node biopsy,&#xD;
             axillary sampling or dissection&#xD;
&#xD;
          -  In those patients with a positive sentinel node biopsy:&#xD;
&#xD;
             o If 1, 2 or 3 nodes are positive, subsequent management of the axilla (with surgery,&#xD;
             radiotherapy or no further intervention) should be completed prior to registration&#xD;
&#xD;
             o If 4 or more nodes are involved, patients must have undergone completion axillary&#xD;
             node dissection&#xD;
&#xD;
          -  Radiotherapy (RT)&#xD;
&#xD;
               -  Patients who have undergone breastconserving surgery should have received&#xD;
                  adjuvant RT&#xD;
&#xD;
               -  Patients who have undergone mastectomy should have received RT if they have more&#xD;
                  than 3 axillary lymph nodes involved&#xD;
&#xD;
               -  Patients who have undergone mastectomy and have T3 tumours and/or 1, 2 or 3&#xD;
                  involved lymph nodes may (or not) have received radiation per institutional&#xD;
                  practice&#xD;
&#xD;
          -  Final histology must fall within at least one of these 3 groups:&#xD;
&#xD;
               -  Node positive&#xD;
&#xD;
               -  Node negative with highrisk features 2 or more of:&#xD;
&#xD;
                    1. ER negative&#xD;
&#xD;
                    2. HER2 positive&#xD;
&#xD;
                    3. Grade 3&#xD;
&#xD;
                    4. Lymphovascular invasion present&#xD;
&#xD;
                    5. Age &lt;35&#xD;
&#xD;
                    6. Oncotype Dx score of &gt;25&#xD;
&#xD;
          -  In patients who have received neoadjuvant chemotherapy, patients are eligible if they&#xD;
             have both a hormone receptor negative/HER2 negative tumour, a HER2 positive tumour or&#xD;
             a hormone receptor positive grade 3 tumour and did not achieve a pathological complete&#xD;
             response with neoadjuvant systemic therapy&#xD;
&#xD;
          -  Known HER2 and ER status&#xD;
&#xD;
          -  Timing of entry&#xD;
&#xD;
             o If no adjuvant chemotherapy or RT: registration within 12 wks of definitive surgery&#xD;
             achieving clear margins&#xD;
&#xD;
             o Following adjuvant chemotherapy/RT: registration within 8 wks of last therapy.&#xD;
&#xD;
          -  Participants may receive endocrine therapy and trastuzumab. All ER positive patients&#xD;
             should be planned to undergo at least 5 yrs of adjuvant endocrine therapy.&#xD;
&#xD;
        COLORECTAL COHORT INCLUSION CRITERIA&#xD;
&#xD;
          -  Histologically confirmed stage II or III adenocarcinoma of the colon or rectum and&#xD;
             patients who have undergone resection of liver metastases with clear margins and no&#xD;
             residual metastatic disease&#xD;
&#xD;
          -  Patients with synchronous tumours if one of the tumours is at least stage II or III&#xD;
&#xD;
          -  Serum CEA ideally ≤1.5 x upper limit of normal&#xD;
&#xD;
          -  Have undergone curative (R0) resection with clear margins&#xD;
&#xD;
          -  Timing of entry:&#xD;
&#xD;
               -  If no adjuvant treatment: registration within 12 wks of definitive surgery&#xD;
                  achieving clear margins&#xD;
&#xD;
               -  Following adjuvant treatment: registration within 8 wks of last therapy&#xD;
                  GASTROOESOPHAGEAL COHORT INCLUSION CRITERIA&#xD;
&#xD;
          -  Patients with histologically confirmed adenocarcinoma, adenosquamous carcinoma or&#xD;
             squamous cell cancer of the oesophagus, gastrooesophageal junction or stomach&#xD;
&#xD;
          -  Have undergone curative (R0) resection with clear margins or primary chemoRT given&#xD;
             with curative intent&#xD;
&#xD;
          -  Timing of entry:&#xD;
&#xD;
               -  Following surgery without adjuvant treatment: registration within 12 wks of the&#xD;
                  definitive surgery achieving clear margins&#xD;
&#xD;
               -  Following primary chemoRT or surgery with adjuvant treatment: registration within&#xD;
                  8 wks of last therapy&#xD;
&#xD;
        PROSTATE COHORT INCLUSION CRITERIA&#xD;
&#xD;
          -  Men with histologically confirmed node negative nonmetastatic adenocarcinoma of the&#xD;
             prostate&#xD;
&#xD;
          -  Have undergone curative treatment, either:&#xD;
&#xD;
               -  Radical prostatectomy&#xD;
&#xD;
               -  Radical RT&#xD;
&#xD;
          -  Intermediate or high risk according to D'Amico classification Depending on the&#xD;
             curative treatment pathway, participant must additionally satisfy the following (a)&#xD;
             Prostatectomy patients&#xD;
&#xD;
          -  Open, laparoscopic or robotic radical prostatectomy&#xD;
&#xD;
          -  Men treated with immediate adjuvant RT&#xD;
&#xD;
          -  Men receiving adjuvant hormone therapy planned for a maximum duration of 3 yrs&#xD;
&#xD;
          -  Timing of entry:&#xD;
&#xD;
               -  If no adjuvant RT: registration within 12 wks of definitive surgery and PSA at ≥6&#xD;
                  weeks postsurgery must be &lt;0.1ng/ml&#xD;
&#xD;
               -  Following adjuvant RT: registration within 8 wks of delivery of final fraction of&#xD;
                  RT&#xD;
&#xD;
               -  Men treated with salvage RT following a rise in PSA&#xD;
&#xD;
          -  Men randomised to RADICALSHD (ISRCTN 40814031) provided all other eligibility criteria&#xD;
             are met (b) Radical RT patients&#xD;
&#xD;
          -  Men receiving neoadjuvant and/or adjuvant hormone therapy planned for a maximum&#xD;
             duration of 3yrs&#xD;
&#xD;
          -  Timing of registration within 8wks from completion of RT (c) Salvage RT patients after&#xD;
             previous Radical Prostatectomy&#xD;
&#xD;
          -  Men treated with salvage RT following a rise in PSA&#xD;
&#xD;
          -  Men receiving neoand/ or adjuvant hormone therapy planned for a maximum of 3yrs&#xD;
&#xD;
        COMMON EXCLUSION CRITERIA&#xD;
&#xD;
        • Current or previous regular use of aspirin (at any dose) or current use of another NSAID&#xD;
        for any indication.&#xD;
&#xD;
          -  A past history of adverse reaction or hypersensitivity to NSAIDs, celecoxib, aspirin&#xD;
             or other salicylates or sulphonamides, including asthma, that is exacerbated by use of&#xD;
             NSAIDs.&#xD;
&#xD;
          -  Current use of anticoagulants.&#xD;
&#xD;
          -  Current or longterm use of oral corticosteroids. The treating physician should make&#xD;
             the clinical decision whether a patient has been exposed to longterm therapy.&#xD;
&#xD;
          -  Active or previous peptic ulceration&#xD;
&#xD;
          -  Previous gastrointestinal bleeding except where the cause of the bleeding has been&#xD;
             surgically removed.&#xD;
&#xD;
          -  Active or previous history of inflammatory bowel disease.&#xD;
&#xD;
          -  History of moderate or severe renal impairment, with eGFR&lt;45ml/min/1.73m2.&#xD;
&#xD;
          -  Previous invasive or noninvasive malignancy except:&#xD;
&#xD;
             - DCIS where treatment consisted of resection alone. Prostate cancer initially treated&#xD;
             with prostatectomy and now being treated with salvage radiotherapy following a rise in&#xD;
             PSA.&#xD;
&#xD;
             - Cervical carcinoma in situ where treatment consisted of resection alone.&#xD;
&#xD;
               -  Basal cell carcinoma where treatment consisted of resection alone or&#xD;
                  radiotherapy.&#xD;
&#xD;
               -  Superficial bladder carcinoma where treatment consisted of resection alone.&#xD;
&#xD;
               -  Other cancers where the patient has been diseasefree for ≥15 years.&#xD;
&#xD;
          -  Any other physical condition which is associated with increased risk of aspirinrelated&#xD;
             morbidity or, in the opinion of the Investigator, makes the patient unsuitable for the&#xD;
             trial, including but not limited to severe asthma, haemophilia and other bleeding&#xD;
             diatheses, macular degeneration and patients with a highrisk of mortality from another&#xD;
             cause within the trial treatment period.&#xD;
&#xD;
          -  Known glucose6phosphate dehydrogenase deficiency.&#xD;
&#xD;
          -  LFTs greater than 1.5x the upper limit of normal unless agreed with TMG.&#xD;
&#xD;
          -  Anticipated difficulties in complying with trial treatment or followup schedules.&#xD;
&#xD;
          -  &lt;16 years old.&#xD;
&#xD;
          -  Participants in other treatment trials where this has not been agreed in advance by&#xD;
             both trial teams.&#xD;
&#xD;
        BREAST COHORT EXCLUSION CRITERIA&#xD;
&#xD;
        • Metastatic or bilateral breast cancer.&#xD;
&#xD;
        COLORECTAL COHORT EXCLUSION CRITERIA • Proven (or clinically suspected) metastatic disease&#xD;
        (patients who have undergone resection of liver metastases with clear margins and no&#xD;
        residual metastatic disease are eligible).&#xD;
&#xD;
        GASTROOESOPHAGEAL COHORT EXCLUSION CRITERIA&#xD;
&#xD;
        • Proven (or clinically suspected) metastatic disease.&#xD;
&#xD;
        PROSTATE COHORT EXCLUSION CRITERIA&#xD;
&#xD;
          -  Biopsy proven or radiologically suspected nodal involvement, or distant metastases&#xD;
             from prostate cancer.&#xD;
&#xD;
          -  Adjuvant hormone therapy planned for &gt;3 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruth Langley</last_name>
    <role>Study Director</role>
    <affiliation>MRC CTU at UCL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gemma Sancha</last_name>
    <phone>02076704759</phone>
    <email>mrcctu.add-aspirin@ucl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alex Robbins</last_name>
    <phone>02076704906</phone>
    <email>mrcctu.add-aspirin@ucl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bon Secours Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mater Private Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Luke's Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tallaght University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College Hospital Galway</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Limerick</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sligo University Hospital</name>
      <address>
        <city>Sligo</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Waterford</name>
      <address>
        <city>Waterford</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>William Harvey Hospital</name>
      <address>
        <city>Ashford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stoke Mandeville Hospital</name>
      <address>
        <city>Aylesbury</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ysbyty Gwynedd</name>
      <address>
        <city>Bangor</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Devon District Hospital</name>
      <address>
        <city>Barnstaple</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Basildon Hospital</name>
      <address>
        <city>Basildon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bedford Hospital</name>
      <address>
        <city>Bedford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Victoria Hospital</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Glan Clwyd Hospital</name>
      <address>
        <city>Bodelwyddan</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pilgrim Hospital</name>
      <address>
        <city>Boston</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology &amp; Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Suffolk Hospital</name>
      <address>
        <city>Bury St Edmunds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fairfield Hospital</name>
      <address>
        <city>Bury</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kent and Canterbury Hospital</name>
      <address>
        <city>Canterbury</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Velindre Hospital</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cumberland Infirmary</name>
      <address>
        <city>Carlisle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cheltenham General Hospital</name>
      <address>
        <city>Cheltenham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Coventry and Warwickshire</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Darlington Memorial Hospital</name>
      <address>
        <city>Darlington</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Darent Valley Hospital</name>
      <address>
        <city>Dartford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Middlesex Hospital</name>
      <address>
        <city>Edmonton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Gateshead</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The New Victoria Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inverclyde Royal Hospital,</name>
      <address>
        <city>Greenock</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Harlow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwick Park Hospital</name>
      <address>
        <city>Harrow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wycombe Hospital</name>
      <address>
        <city>High Wycombe</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hinchingbrooke Hospital</name>
      <address>
        <city>Huntingdon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Raigmore Hospital</name>
      <address>
        <city>Inverness</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ipswich Hospital</name>
      <address>
        <city>Ipswich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Airedale General Hospital</name>
      <address>
        <city>Keighley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kidderminster General Hospital</name>
      <address>
        <city>Kidderminster</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kingston Hospital</name>
      <address>
        <city>Kingston</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Lancaster Infirmary</name>
      <address>
        <city>Lancaster</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lincoln County Hospital</name>
      <address>
        <city>Lincoln</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St George's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Luton &amp; Dunstable Hospital</name>
      <address>
        <city>Luton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Manchester General Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital,</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth The Queen Mother Hospital</name>
      <address>
        <city>Margate</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Milton Keynes University Hospital</name>
      <address>
        <city>Milton Keynes</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Friarage Hospital</name>
      <address>
        <city>Northallerton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northampton General Hospital</name>
      <address>
        <city>Northampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>George Eliot Hospital</name>
      <address>
        <city>Nuneaton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Oldham Hospital</name>
      <address>
        <city>Oldham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Alexandra Hospital</name>
      <address>
        <city>Paisley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Alexandra Hospital</name>
      <address>
        <city>Portsmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Berkshire Hospital</name>
      <address>
        <city>Reading</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alexandra Hospital</name>
      <address>
        <city>Redditch</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>East Surrey Hospital</name>
      <address>
        <city>Redhill</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen's Hospital</name>
      <address>
        <city>Romford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Salisbury District Hospital</name>
      <address>
        <city>Salisbury</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lister Hospital</name>
      <address>
        <city>Stevenage</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>King's Mill Hospital</name>
      <address>
        <city>Sutton-in-Ashfield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Singleton Hospital</name>
      <address>
        <city>Swansea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Great Western Hospital</name>
      <address>
        <city>Swindon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weston General Hospital</name>
      <address>
        <city>Weston Super Mare</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Cumberland Hospital</name>
      <address>
        <city>Whitehaven</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Albert Edward Infirmary</name>
      <address>
        <city>Wigan</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Worcestershire Royal Hospital</name>
      <address>
        <city>Worcester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wrexham Maelor Hospital</name>
      <address>
        <city>Wrexham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 12, 2016</study_first_submitted>
  <study_first_submitted_qc>June 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2016</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aspirin</keyword>
  <keyword>prostate</keyword>
  <keyword>colorectal</keyword>
  <keyword>breast</keyword>
  <keyword>gastro-oesophageal</keyword>
  <keyword>recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

